<DOC>
	<DOCNO>NCT01399346</DOCNO>
	<brief_summary>Rationale : For development close loop system , fast insulin absorption bolus administration could help reduce system 's delay thus increase patient safety . It show regular insulin absorption faster inject insulin sprinkler needle ( contain hole wall seal tip ) . The current study evaluate impact different application volume pharmacokinetic pharmacodynamic property rapid act insulin analogue ( insulin aspart ) . Objective : To compare pharmacokinetic response ( base time maximum observed serum insulin concentration ) pharmacodynamic property rapid act insulin aspart subcutaneous injection define dose ( volume ) 1 versus 9 injection site patient type 1 diabetes . Study design : Monocentric , randomise , control , two-arm cross-over intervention study . Population : Twelve type 1 diabetic subject Intervention : The investigational treatment subcutaneous administration insulin aspart either one bolus 18 IU one injection site 9 separately simultaneously apply bolus 2 IU 9 separate injection site . Serum plasma sample assess pharmacodynamic pharmacokinetic property take 8-hour clamp experiment . Patients undergo investigational treatment randomize order ; two clamp visit wash-out period 5-21 day . Main study endpoint : Time maximum observed serum insulin aspart concentration .</brief_summary>
	<brief_title>Investigation Impact Different Application Volumes Insulin Aspart Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Informed consent obtain advised nature study Male female age 1860 year ( inclusive ) Type 1 diabetes treat multiple daily insulin injection continuous subcutaneous insulin infusion 12 month Fasting Cpeptide &lt; 0.3nmol/L Body mass index 20.028.0 kg/mÂ² ( inclusive ) HbA1c &lt; 10 % Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method Skin pathology condition prohibit needle insertion/insulin administration judge investigator History bleed disorder Current participation another clinical study Significant acute chronic illness might interfere subject safety integrity result judge investigator Smoker ( define &gt; 5 cigarettes/d ) Lipodystrophy Current treatment systemic ( oral i.v . ) corticosteroid , monoamine oxidase ( MAO ) inhibitor , nonselective betablockers , growth hormone , herbal product nonroutine vitamin . Furthermore , thyroid hormone allow unless use stable past 3 month . Significant history alcoholism drug abuse positive result urine drug/alcohol screen . Study Day Strenuous exercise within last 24 hour prior dose . Nonfasting ( i.e . consumption food beverage , water , later 22:00 hour even visit ) except slight intake rapidly absorbable carbohydrate necessary order prevent hypoglycaemia . Injection longacting insulin ( e.g . insulin glargine insulin detemir ) later 12:00 hour ( noon ) , 2 day dose visit . Injection NPH insulin intermediateacting insulin product later 12:00 hour ( noon ) day dose visit . Injection short act insulin ( aspart , lispro , glulisine ) 6 IU human insulin 22:00 hour 03:00 hour night dose visit . Injection insulin later 03:00 hour night dose visit . Infusion insulin later 03:00 hour night dose visit subject use continuous subcutaneous insulin infusion ( CSII ) . Positive result alcohol breath test . Any medical condition , opinion Investigator , could interfere insulin pharmacokinetics and/or glucose metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Insulin aspart</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Glucose clamp</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Rapid Acting Insulin Analog</keyword>
</DOC>